Topics

VIVUS, Inc. Company Profile

07:05 EST 7th December 2019 | BioPortfolio

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.


News Articles [32 Associated News Articles listed on BioPortfolio]

VIVUS enrols first patient in Phase IV trial of Qsymia

VIVUS has started patient enrolment in a Phase IV clinical trial of Qsymia (phentermine and topiramate, extended-release) capsules in obese...Read More... The post VIVUS enrols first patient in Phase ...

Vivus amends agreement with Nordmark for Pancreaze capsules

Vivus has amended its manufacturing and supply agreement with Nordmark Arzneimittel for Pancreaze (pancrelipase) delayed-release capsules covering an initial term...Read More... The post Vivus amends ...

Coming In Monday's "The Pink Sheet" DAILY - EMA Panel Again Rejects Vivus' Obesity Drug Qsiva

European Medicines Agency committee recommends Vivus' Qsiva not be approved - Financings of the Fortnight looks at pending IPOs - Kolltan Pharmaceuticals prepares to move to new stage - Compounding ph...

VIVUS to Present at Upcoming Conferences

CAMPBELL, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIV...

VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes

-Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million--Organizational change streamlines commercial operations- CAMPBELL, Calif., Oct. 03, 201...

VIVUS Reports Third Quarter 2019 Financial Results

CAMPBELL, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of ...

VIVUS Reports First Quarter 2019 Financial Results

Company to host conference call today at 4:30pm ET CAMPBELL, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed ...

VIVUS Announces Approval of Qsymia® in the Republic of Korea

VIVUS receives $2.5 million milestone payment CAMPBELL, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that ...

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Pancreaze [vivus, inc.]

These highlights do not include all the information needed to use PANCREAZE safely and effectively. See full prescribing information for PANCREAZE . PANCREAZE (pancrelipase) delayed-release capsules I...

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Multi-Center Study to Evaluate Estradiol Transdermal Spray in the Treatment of Symptomatic Postmenopausal Women

Estradiol treatment is effective at reducing vasomotor symptoms (eg, hot flushes) in postmenopausal women. Vivus has a proprietary spray delivery system (Evamist) for estradiol. This stu...

Companies [3 Associated Companies listed on BioPortfolio]

VIVUS, Inc.

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed p...

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the pot...

Aventyn, Inc.

Aventyn is the first company to deliver innovative secure connected information processing solutions with its standards based CLIP® solution to efficiently manage health inform...

More Information about "VIVUS, Inc." on BioPortfolio

We have published hundreds of VIVUS, Inc. news stories on BioPortfolio along with dozens of VIVUS, Inc. Clinical Trials and PubMed Articles about VIVUS, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of VIVUS, Inc. Companies in our database. You can also find out about relevant VIVUS, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Sleep Disorders
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...


Corporate Database Quicklinks



Searches Linking to this Company Record